Related Experiment Video

Updated: Aug 14, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Options for treatment of hepatitis C in HIV-infected persons

David L Thomas1

  • 1Johns Hopkins School of Medicine, 1503 East Jefferson Street, Baltimore, MD 21231, USA.

Journal of Hepatology
|December 17, 2005
PubMed

Insights

The optimal treatment for hepatitis C virus (HCV) infection is peginterferon alpha and ribavirin, with higher success rates in specific genotypes and lower viral loads. However, HIV coinfection complicates treatment and reduces sustained virologic response (SVR) rates.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Virology

Background:

  • Hepatitis C virus (HCV) infection affects millions globally, with coinfection by human immunodeficiency virus (HIV) presenting unique challenges.
  • Peginterferon alpha and ribavirin are established treatments for HCV, but their efficacy and safety in HIV-coinfected individuals require careful consideration.

Purpose of the Study:

  • To evaluate the optimal treatment strategies for HCV infection, considering the impact of HIV coinfection.
  • To compare sustained virologic response (SVR) rates and adverse effects in HIV-infected versus uninfected individuals undergoing HCV treatment.

Main Methods:

  • The study reviews current treatment guidelines and research findings on HCV therapy with peginterferon alpha and ribavirin.
  • Analysis focuses on factors influencing SVR, including HCV genotype, baseline viral load, and HIV status.

Main Results:

  • SVR rates are higher for HCV genotypes 2 and 3 and in patients with lower pre-treatment HCV RNA levels, irrespective of HIV status.
  • HIV coinfection is associated with lower SVR rates and potential drug interactions between ribavirin and antiretroviral medications.
  • Adverse treatment effects are similar, but managing HCV in HIV-infected individuals is complex due to drug interactions and effects on HIV progression.

Conclusions:

  • Peginterferon alpha and ribavirin remain the optimal treatment for HCV, but HIV coinfection necessitates tailored approaches.
  • Further research is crucial to improve current therapies and develop new antiviral agents for HIV/HCV coinfected patients to enhance SVR outcomes.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...